Filing Details
- Accession Number:
- 0000891293-12-000042
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-06-29 20:36:15
- Reporting Period:
- 2012-06-27
- Filing Date:
- 2012-06-29
- Accepted Time:
- 2012-06-29 19:36:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
891293 | Cell Therapeutics Inc | CTIC | Pharmaceutical Preparations (2834) | 911533912 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1204264 | W Jack Singer | 3101 Western Avenue, Suite 600 Seattle WA 98121 | Evp, Global Medical Affairs | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-06-27 | 37,161 | $0.00 | 2,527,534 | No | 4 | A | Direct | |
Common Stock | Disposition | 2012-06-29 | 11,260 | $0.60 | 2,516,274 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-06-29 | 200 | $0.60 | 2,516,074 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-06-29 | 11,370 | $0.60 | 2,504,704 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-06-29 | 1,100 | $0.60 | 2,503,604 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-06-29 | 26,070 | $0.60 | 2,477,534 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- As disclosed by CTIC in a Form 8-K filed on 12/1/11, CTIC granted a bonus opportunity to the reporting person that is payable in shares of CTIC stock upon the achievement of certain performance goals. The shares reported above on this Form 4 reflect the issuance of vested stock by CTIC pursuant to the award in connection with the achievement of the Pixantrone MAA Approval goal under the award.